Kate Gunn: Director Ms Kate Gunn is the Chief Operating Officer at the Garvan Institute of Medical Research. Kate has 25 years of business experience and prior to joining Garvan was the COO of the ARC Centre of Excellence for All-sky Astrophysics (CAASTRO) at Sydney University. She is also the Founder and Director of Balance! Healthcare. Balance! Healthcare is a leader in multi-disciplinary integrated primary healthcare, and has practices in NSW and QLD. In 2015, Kate won a scholarship from Chief Executive Women and the Women’s Leadership Institute to attend the Women’s Leadership Program, Harvard Business School, and in 2012 she was named as one of the inaugural 100 Women of Influence in Australia (by Westpac and the Australian Financial Review).
Remy Robert: Director Dr Robert is a research fellow in the Department of Molecular Biology and Biochemistry (Monash University) and leads the efforts at Monash further devloping antibodies licensed from G2. Dr Robert is an expert in therapeutic antibody development and antibody engineering. In 2007 he was awarded the prestigious CSIRO OCE (Office of the Chief Executive) Postdoctoral Fellowship. Dr Robert’s goal is to move academic science into translation in the form of new antibody therapies using cutting-edge protein engineering techniques and human receptor knock-in mice.
Andrew Adamovich: Director Mr Andrew Adamovich is a Founder and Director of Riverland Capital Limited, Director of Amara Enterprises Limited, Yuan Chuan
(Cayman) Limited, China Education Corporation, and ASX-listed Ambition Group
Limited. Previously Andrew was an Associate with the Zurich Centre Group
and a Director at Equity Partners Asia Limited. Mr. Adamovich has over ten
years experience in finance, focused on direct investment in Asia. Mr.
Adamovich has a Bachelor of Arts degree from the University of California,
Peter Whitfeld: Company Secretary & General Manager Dr Peter Whitfeld has over 25 years experience in biotechnology research, development and management. He is currently a Senoir Manager in the Partnerships Office at the Garvan Institute and also manages the C5aR program at G2 Therapies. Previously he lead the team responsible for humanising G2's therapeutic antibodies and was a senior staff member in the Immunology and Inflammation Research Program at the Garvan Institute. Prior to joining G2 and the Garvan, Dr Whitfeld held senior research and managerial positions at GroPep and Biotech Australia. He held post doctoral research positions at CSIRO, Fox Chase Cancer Center and Prince Henrys Institute for Medical Research after completing a PhD at the Australian National University, Research School of Biological Sciences.